astragaloside a has been researched along with Cancer of Liver in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, H; Wu, C; Zhao, J | 1 |
| Gao, H; Hu, T; Qu, X; Song, Y; Sun, J; Tao, L; Zhai, J; Zhang, Y | 1 |
| Cui, X; Jiang, X; Tong, G; Wei, C; Xing, Y | 1 |
| Luan, JJ; Wang, L; Wang, PP; Wang, YQ; Xu, DJ; Xu, WK; Yang, CY; Zhu, YH | 1 |
| Chen, H; Li, Y; Ye, Y | 1 |
| Huang, C; Wang, PP; Wang, WP; Xu, DJ; Xu, WK | 1 |
| Boye, A; Jiang, Y; Wang, J; Wu, C; Wu, J; Yang, X; Yang, Y | 1 |
| Cao, MQ; Gao, DM; Ma, DN; Qin, CD; Ren, ZG; Tang, ZY; Wang, CH; Wang, YC; Ye, BG; Zhu, XD | 1 |
| Dai, J; Guo, X; Hoffman, RM; Sun, YU; Tang, D; Yang, Z; Yin, G; Zang, W; Zhang, S | 1 |
| Han, Y; Lau, AS; Qi, H; Rong, J; Wei, L; Zhang, Q | 1 |
10 other study(ies) available for astragaloside a and Cancer of Liver
| Article | Year |
|---|---|
Astragaloside IV-enhanced anti-hepatocarcinoma immunity of dendritic cells.
Topics: Carcinoma, Hepatocellular; Dendritic Cells; Humans; Liver Neoplasms; Saponins; Triterpenes | 2022 |
Astragaloside IV enhances cisplatin chemosensitivity in hepatocellular carcinoma by suppressing MRP2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Interactions; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Kidney; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Saponins; Triterpenes | 2020 |
Astragaloside IV suppresses development of hepatocellular carcinoma by regulating miR-150-5p/β-catenin axis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Saponins; Triterpenes | 2020 |
Astragaloside IV downregulates the expression of MDR1 in Bel‑7402/FU human hepatic cancer cells by inhibiting the JNK/c‑Jun/AP‑1 signaling pathway.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Fluorouracil; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; Saponins; Signal Transduction; Transcription Factor AP-1; Triterpenes | 2017 |
Astragaloside IV inhibits cell migration and viability of hepatocellular carcinoma cells via suppressing long noncoding RNA ATB.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Down-Regulation; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Interleukin-11; Liver Neoplasms; RNA, Long Noncoding; Saponins; STAT3 Transcription Factor; Triterpenes | 2018 |
Astragaloside Ⅳ reduces the expression level of P-glycoprotein in multidrug-resistant human hepatic cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Rhodamine 123; Saponins; Triterpenes | 2014 |
Compound Astragalus and Salvia miltiorrhiza extracts modulate MAPK-regulated TGF-β/Smad signaling in hepatocellular carcinoma by multi-target mechanism.
Topics: Alkenes; Animals; Astragalus propinquus; Carcinoma, Hepatocellular; Diethylnitrosamine; Down-Regulation; Gene Expression; Hep G2 Cells; Hepatic Stellate Cells; Humans; Karyopherins; Liver Neoplasms; Male; MAP Kinase Signaling System; Plant Extracts; Plasminogen Activator Inhibitor 1; Polyphenols; Polysaccharides; Rats; Receptors, Cytoplasmic and Nuclear; Salvia miltiorrhiza; Saponins; Signal Transduction; Smad2 Protein; Transforming Growth Factor beta1; Triterpenes; Up-Regulation | 2015 |
Astragaloside IV inhibits metastasis in hepatoma cells through the suppression of epithelial-mesenchymal transition via the Akt/GSK-3β/β-catenin pathway.
Topics: beta Catenin; Blotting, Western; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Humans; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Saponins; Signal Transduction; Triterpenes; Tumor Cells, Cultured | 2017 |
Synergistic Inhibitory Effect of Traditional Chinese Medicine Astragaloside IV and Curcumin on Tumor Growth and Angiogenesis in an Orthotopic Nude-Mouse Model of Human Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Growth Processes; Curcumin; Disease Models, Animal; Down-Regulation; Drug Synergism; Hep G2 Cells; Heterografts; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Random Allocation; Saponins; Triterpenes | 2017 |
Proteomic characterization of the cellular response to chemopreventive triterpenoid astragaloside IV in human hepatocellular carcinoma cell line HepG2.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; DNA Primers; Electrophoresis, Gel, Two-Dimensional; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mass Spectrometry; Peptides; Plant Preparations; Proteomics; Reverse Transcriptase Polymerase Chain Reaction; Saponins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Triterpenes | 2010 |